留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植受者术前心脏疾病风险评估的现状及展望

李文磊, 栗光明. 肝移植受者术前心脏疾病风险评估的现状及展望[J]. 器官移植, 2023, 14(4): 605-611. doi: 10.3969/j.issn.1674-7445.2023.04.019
引用本文: 李文磊, 栗光明. 肝移植受者术前心脏疾病风险评估的现状及展望[J]. 器官移植, 2023, 14(4): 605-611. doi: 10.3969/j.issn.1674-7445.2023.04.019
Li Wenlei, Li Guangming. Current status and prospect of preoperative assessment of heart disease risk in liver transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(4): 605-611. doi: 10.3969/j.issn.1674-7445.2023.04.019
Citation: Li Wenlei, Li Guangming. Current status and prospect of preoperative assessment of heart disease risk in liver transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(4): 605-611. doi: 10.3969/j.issn.1674-7445.2023.04.019

肝移植受者术前心脏疾病风险评估的现状及展望

doi: 10.3969/j.issn.1674-7445.2023.04.019
基金项目: 

北京市医院管理中心重点医学专业发展计划 ZYLX202124

吴阶平医学基金 320.6750.2022-03-55

详细信息
    作者简介:
    通讯作者:

    Li Guangming, Email: liguangming@ccmu.edu.cn

  • 中图分类号: R617, R541

Current status and prospect of preoperative assessment of heart disease risk in liver transplant recipients

  • 摘要: 随着肝移植疾病谱和器官分配体系等因素的改变,越来越多伴有心血管合并症的患者进入移植等待名单。手术应激、严重感染、免疫抑制药物不良反应等亦会导致术后心脏并发症发生风险显著增加,影响受者短期及长期生存。因此,术前对受者心脏结构及功能进行全面评估,对改善肝移植预后尤其重要。本文就肝移植围手术期心脏疾病风险增加的主要原因、肝移植受者心脏疾病风险评估的时机和方法进行综述,介绍当前肝移植术前常见心脏疾病的评估手段,以期为进一步降低肝移植术后心脏并发症发生率、提高移植物和受者存活率、改善临床预后结果提供参考。

     

  • [1] IZZY M, FORTUNE BE, SERPER M, et al. Management of cardiac diseases in liver transplant recipients: comprehensive review and multidisciplinary practice-based recommendations[J]. Am J Transplant, 2022, 22(12): 2740-2758. DOI: 10.1111/ajt.17049.
    [2] CASE BC, YANG M, QAMER SZ, et al. Pre-operative cardiovascular testing before liver transplantation[J]. Am J Cardiol, 2021, 152: 132-137. DOI: 10.1016/j.amjcard.2021.04.012.
    [3] KOSHY AN, GOW PJ, HAN HC, et al. Sudden cardiac death following liver transplantation: incidence, trends and risk predictors[J]. Int J Cardiol, 2021, 327: 171-174. DOI: 10.1016/j.ijcard.2020.11.038.
    [4] BARMAN PM, VANWAGNER LB. Cardiac risk assessment in liver transplant candidates: current controversies and future directions[J]. Hepatology, 2021, 73(6): 2564-2576. DOI: 10.1002/hep.31647.
    [5] VILLERET F, DHARANCY S, ERARD D, et al. Liver transplantation for NAFLD cirrhosis: age and recent coronary angioplasty are major determinants of survival[J]. Liver Int, 2022, 42(11): 2428-2441. DOI: 10.1111/liv.15385.
    [6] 靳婕华, 黄缘. 肝移植治疗非酒精性脂肪性肝病的现状[J/CD]. 实用器官移植电子杂志, 2022, 10(2): 152-157. DOI: 10.3969/j.issn.2095-5332.2022.02.013.

    JIN JH, HUANG Y. Current status of liver transplantation in the treatment of nonalcoholic fatty liver disease[J/CD]. Pract J Organ Transplant (Electr Vers), 2022, 10(2): 152-157. DOI: 10.3969/j.issn.2095-5332.2022.02.013.
    [7] IZZY M, SOLDATOVA A, SUN X, et al. Cirrhotic cardiomyopathy predicts posttransplant cardiovascular disease: revelations of the new diagnostic criteria[J]. Liver Transpl, 2021, 27(6): 876-886. DOI: 10.1002/lt.26000.
    [8] IZZY M, VANWAGNER LB, LIN G, et al. Redefining cirrhotic cardiomyopathy for the modern era[J]. Hepatology, 2020, 71(1): 334-345. DOI: 10.1002/hep.30875.
    [9] FELTRACCO P, BARBIERI S, CAROLLO C, et al. Early circulatory complications in liver transplant patients[J]. Transplant Rev (Orlando), 2019, 33(4): 219-230. DOI: 10.1016/j.trre.2019.06.005.
    [10] MALIK MU, RUSSELL SD, PUSTAVOITAU A, et al. The predictors of post-transplant coronary events among liver transplant recipients[J]. Hepatol Int, 2016, 10(6): 974-982. DOI: 10.1007/s12072-016-9742-5.
    [11] VANWAGNER LB, NING H, WHITSETT M, et al. A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: the CAR-OLT score[J]. Hepatology, 2017, 66(6): 1968-1979. DOI: 10.1002/hep.29329.
    [12] LEVY PE, KHAN SS, VANWAGNER LB. Cardiac evaluation of the kidney or liver transplant candidate[J]. Curr Opin Organ Transplant, 2021, 26(1): 77-84. DOI: 10.1097/MOT.0000000000000838.
    [13] KHURMI NS, CHANG YH, ERIC STEIDLEY D, et al. Hospitalizations for cardiovascular disease after liver transplantation in the United States[J]. Liver Transpl, 2018, 24(10): 1398-1410. DOI: 10.1002/lt.25055.
    [14] VANWAGNER LB, HOLL JL, MONTAG S, et al. Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients[J]. Am J Transplant, 2020, 20(3): 797-807. DOI: 10.1111/ajt.15706.
    [15] XIAO J, YONG JN, NG CH, et al. A meta-analysis and systematic review on the global prevalence, risk factors, and outcomes of coronary artery disease in liver transplantation recipients[J]. Liver Transpl, 2022, 28(4): 689-699. DOI: 10.1002/lt.26331.
    [16] KAKAR P, GUBITOSA J, GERULA C. Echocardiography in the liver transplant patient[J]. Curr Cardiol Rep, 2021, 23(8): 110. DOI: 10.1007/s11886-021-01531-1.
    [17] PATEL SS, LIN FP, RODRIGUEZ VA, et al. The relationship between coronary artery disease and cardiovascular events early after liver transplantation[J]. Liver Int, 2019, 39(7): 1363-1371. DOI: 10.1111/liv.14092.
    [18] SATAPATHY SK, VANATTA JM, HELMICK RA, et al. Outcome of liver transplant recipients with revascularized coronary artery disease: a comparative analysis with and without cardiovascular risk factors[J]. Transplantation, 2017, 101(4): 793-803. DOI: 10.1097/TP.0000000000001647.
    [19] WEBERLING LD, LOSSNITZER D, FREY N, et al. Coronary computed tomography vs. cardiac magnetic resonance imaging in the evaluation of coronary artery disease[J]. Diagnostics (Basel), 2022, 13(1): 125. DOI: 10.3390/diagnostics13010125.
    [20] CHENG XS, VANWAGNER LB, COSTA SP, et al. Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: a scientific statement from the american heart association: endorsed by the american society of transplantation[J]. Circulation, 2022, 146(21): e299-e324. DOI: 10.1161/CIR.0000000000001104.
    [21] DE GASPERI A, SPAGNOLIN G, ORNAGHI M, et al. Preoperative cardiac assessment in liver transplant candidates[J]. Best Pract Res Clin Anaesthesiol, 2020, 34(1): 51-68. DOI: 10.1016/j.bpa.2020.02.002.
    [22] 杨鑫, 杨叶, 张婉婷, 等. 基于CT-FFR在冠状动脉功能性狭窄评估中的应用进展[J]. 影像研究与医学应用, 2023, 7(4): 18-20. DOI: 10.3969/j.issn.2096-3807.2023.04.006.

    YANG X, YANG Y, ZHANG WT, et al. Progress based on the application of CT-FFR in the evaluation of functional stenosis of coronary arteries[J]. J Imaging Res Med Appl, 2023, 7(4): 18-20. DOI: 10.3969/j.issn.2096-3807.2023.04.006.
    [23] KEMMER N, CASE J, CHANDNA S, et al. The role of coronary calcium score in the risk assessment of liver transplant candidates[J]. Transplant Proc, 2014, 46(1): 230-233. DOI: 10.1016/j.transproceed.2013.09.035.
    [24] SHARMA V, KLEB C, SHETH C, et al. Cardiac considerations in liver transplantation[J]. Cleve Clin J Med, 2022, 89(1): 46-55. DOI: 10.3949/ccjm.89a.21006.
    [25] CANTONI V, GREEN R, ACAMPA W, et al. Diagnostic performance of myocardial perfusion imaging with conventional and CZT single-photon emission computed tomography in detecting coronary artery disease: a metaanalysis[J]. J Nucl Cardiol, 2021, 28(2): 698-715. DOI: 10.1007/s12350-019-01747-3.
    [26] DANAD I, SZYMONIFKA J, TWISK JWR, et al. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis[J]. Eur Heart J, 2017, 38(13): 991-998. DOI: 10.1093/eurheartj/ehw095.
    [27] KASSAB K, DOUKKY R. Cardiac imaging for the assessment of patients being evaluated for liver transplantation[J]. J Nucl Cardiol, 2022, 29(3): 1078-1090. DOI: 10.1007/s12350-021-02591-0.
    [28] DUVALL WL, SINGHVI A, TRIPATHI N, et al. SPECT myocardial perfusion imaging in liver transplantation candidates[J]. J Nucl Cardiol, 2020, 27(1): 254-265. DOI: 10.1007/s12350-018-1388-3.
    [29] TORⅡ R, YACOUB MH. CT-based fractional flow reserve: development and expanded application[J]. Glob Cardiol Sci Pract, 2021, 2021(3): e202120. DOI: 10.21542/gcsp.2021.20.
    [30] PATEL SS, NABI E, GUZMAN L, et al. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation[J]. Liver Transpl, 2018, 24(3): 333-342. DOI: 10.1002/lt.25012.
    [31] BONOU M, MAVROGENI S, KAPELIOS CJ, et al. Preoperative evaluation of coronary artery disease in liver transplant candidates: many unanswered questions in clinical practice[J]. Diagnostics (Basel), 2021, 11(1): 75. DOI: 10.3390/diagnostics11010075.
    [32] ROMERO-CRISTÓBAL M, MOMBIELA T, CABALLERO A, et al. Clinical utility of a riskadapted protocol for the evaluation of coronary artery disease in liver transplant recipients[J]. Liver Transpl, 2019, 25(8): 1177-1186. DOI: 10.1002/lt.25493.
    [33] 陈欣, 陈琳. 肝硬化心肌病发病机制与临床相关性研究现况[J]. 肝脏, 2023, 28(1): 121-124. DOI: 10.3969/j.issn.1008-1704.2023.01.029.

    CHEN X, CHEN L. Current status of research on the pathogenesis and clinical relevance of cardiomyopathy with liver cirrhosis[J]. Chin Hepatol, 2023, 28(1): 121-124. DOI: 10.3969/j.issn.1008-1704.2023.01.029.
    [34] MOON YJ, KWON HM, JUNG KW, et al. Risk stratification of myocardial injury after liver transplantation in patients with computed tomographic coronary angiography-diagnosed coronary artery disease[J]. Am J Transplant, 2019, 19(7): 2053-2066. DOI: 10.1111/ajt.15263.
    [35] KASKI JC, CREA F, GERSH BJ, et al. Reappraisal of ischemic heart disease[J]. Circulation, 2018, 138(14): 1463-1480. DOI: 10.1161/CIRCULATIONAHA.118.031373.
    [36] 徐强, 方玮, 孙高亚, 等. 肝硬化心肌病诊断与治疗研究进展[J]. 肝脏, 2022, 27(3): 267-270. DOI: 10.3969/j.issn.1008-1704.2022.03.004.

    XU Q, FANG W, SUN GY, et al. Research progress in the diagnosis and treatment of liver cirrhosis cardiomyopathy[J]. Chin Hepatol, 2022, 27(3): 267-270. DOI: 10.3969/j.issn.1008-1704.2022.03.004.
    [37] 赵敏竹, 杨晋辉, 李玉婷. 肝硬化心肌病的病理特征、发病机制及诊疗进展[J]. 山东医药, 2022, 62(22): 91-94. DOI: 10.3969/j.issn.1002-266X.2022.22.023.

    ZHAO MZ, YANG JH, LI YT. Pathological characteristics, pathogenesis, and diagnosis and treatment progress of liver cirrhosis cardiomyopathy[J]. Shandong Med J, 2022, 62(22): 91-94. DOI: 10.3969/j.issn.1002-266X.2022.22.023.
    [38] 张辉辉, 朱好辉, 张喜君, 等. 压力-应变环定量评价乙型肝炎肝硬化患者左室整体心肌做功[J]. 中华肝脏病杂志, 2022, 30(4): 402-406. DOI: 10.3760/cma.j.cn501113-20210628-00305.

    ZHANG HH, ZHU HH, ZHANG XJ, et al. Quantitative evaluation of global left ventricular myocardial work in patients with hepatitis B cirrhosis by pressure-strain loop[J]. Chin J Hepatol, 2022, 30(4): 402-406. DOI: 10.3760/cma.j.cn501113-20210628-00305.
    [39] 陈宗坤, 孙静, 莱智勇, 等. 肝硬化心肌病诊断评估分析[J]. 中西医结合心脑血管病杂志, 2021, 19(15): 2558-2563. DOI: 10.12102/j.issn.1672-1349.2021.15.013.

    CHEN ZK, SUN J, LAI ZY, et al. Diagnosis and evaluation analysis of cirrhotic cardiomyopathy[J]. Chin J Integr Med Cardio Cerebrovasc Dis, 2021, 19(15): 2558-2563. DOI: 10.12102/j.issn.1672-1349.2021.15.013.
    [40] DOUGLAS PS, DE BRUYNE B, PONTONE G, et al. 1-year outcomes of FFRCT-guided care in patients with suspected coronary disease: the PLATFORM study[J]. J Am Coll Cardiol, 2016, 68(5): 435-445. DOI: 10.1016/j.jacc.2016.05.057.
    [41] TESCHE C, DE CECCO CN, ALBRECHT MH, et al. Coronary CT angiography-derived fractional flow reserve[J]. Radiology, 2017, 285(1): 17-33. DOI: 10.1148/radiol.2017162641.
    [42] 张澍. 精彩2022: 心律失常领域10大研究回顾[J]. 中华心律失常学杂志, 2023, 27(1): 1-4. DOI: 10.3760/cma.j.cn113859-20230106-00001.

    ZHANG S. Top 10 studies of cardiac arrhythmia in 2022[J]. Chin J Card Arrhythm, 2023, 27(1): 1-4. DOI: 10.3760/cma.j.cn113859-20230106-00001.
    [43] SO WZ, TAN FL, TAN DJH, et al. A systematic review and meta-analysis on the impact of pre-existing and newonset atrial fibrillation on outcomes before and after liver transplantation[J]. Dig Liver Dis, 2022, 54(5): 614-621. DOI: 10.1016/j.dld.2021.11.011.
    [44] KOSHY AN, KO J, FAROUQUE O, et al. Effect of QT interval prolongation on cardiac arrest following liver transplantation and derivation of a risk index[J]. Am J Transplant, 2021, 21(2): 593-603. DOI: 10.1111/ajt.16145.
    [45] BERNARDI M, MAGGIOLI C, DIBRA V, et al. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat?[J]. Expert Rev Gastroenterol Hepatol, 2012, 6(1): 57-66. DOI: 10.1586/egh.11.86.
    [46] LEE SH, PARK M, PARK KM, et al. Corrected QT interval on the electrocardiogram after liver transplantation: surrogate marker of poor clinical outcomes?[J]. PLoS One, 2018, 13(10): e0206463. DOI: 10.1371/journal.pone.0206463.
  • 加载中
图(1)
计量
  • 文章访问数:  150
  • HTML全文浏览量:  51
  • PDF下载量:  39
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-05-07
  • 网络出版日期:  2023-07-13
  • 刊出日期:  2023-07-15

目录

    /

    返回文章
    返回